💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rabeprazole

CHEMBL1219 Phase 4 Onaylandı Small molecule
Half-Life
1-2 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
359.4 g/mol
LogP
1.9
Phase
4

A proton pump inhibitor that reduces stomach acid production, used to treat gastroesophageal reflux disease, stomach ulcers, and related conditions. It provides relief from heartburn and helps the esophagus heal from acid damage.

Moleküler Ağırlık

359,4440 g/mol

LogP

1,90

TPSA

96,30 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Asthma Insomnia Infectious Disease Gastroesophageal Reflux Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Atrial Fibrillation Prostate Cancer Colorectal Cancer

İlaç Sınıfları

A — A - Alimentary Tract and Metabolism

Etki Mekanizması

Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

Pharmacokinetics (PK)

Half-Life 1-2 hours

Pharmacodynamics (PD)

Mekanizma

Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C

                

                

                
                

                    
InChI

                    
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H21N3O3S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
8

                    

                    
                    
                    

                        
Ağır Atomlar

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
A proton pump inhibitor that reduces stomach acid production, used to treat gastroesophageal reflux disease, stomach ulcers, and related conditions. It provides relief from heartburn and helps the esophagus heal from acid damage.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Rabeprazole: Half-life: 1-2 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Rabeprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1219.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5029.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.